Drug Trial Radar · NCT07421167
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
164
Planned (sponsor's estimate)
Start
Aug 4, 2026
Primary completion
Jan 18, 2029
Study completion Aug 31, 2030
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the tolerability of ianalumab (9 mg/kg) with investigator's choice thrombopoietin receptor agonist (IC TPO-RA) in participants diagnosed with primary immune thrombocytopenia (ITP) who have been treated with at least one but no more than four prior treatments, and with no change in IC TPO-RA dose in at least the last 14 days prior to the start of ianalumab.
Conditions
- Primary Immune Thrombocytopenia (ITP)
- Primary Evans Syndrome (ES)
Interventions
ianalumabBiological
9 mg per kilogram infusion every 4 weeks (Q4W) for 16 weeks
thrombopoietin receptor agonist (TPO-RA)Drug
IC TPO-RAs will be administered according to the respective United States Prescribing Information (USPIs)
Primary outcomes
What the sponsor says the trial is designed to measure.
- (Main cohort: Primary immune thrombocytopenia (ITP)): Percentages of participants who are tolerable to ianalumab (9 mg/kg)Time frame: Up to Week 16
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Ironwood Cancer and Research Centers
Chandler, Arizona · Recruiting
Highlands Oncology Group
Fayetteville, Arkansas · Recruiting
Harbor-UCLA Medical Center
Torrance, California · Recruiting
Lutheran Hospital Cancer Centers
Golden, Colorado · Recruiting
Yale Cancer Center
New Haven, Connecticut · Recruiting
Stamford Hospital
Stamford, Connecticut · Recruiting
Baptist MD Anderson Cancer Center
Jacksonville, Florida · Recruiting
DH Cancer Research Center LLC
Margate, Florida · Recruiting
University Of Miami
Miami, Florida · Recruiting
Advent Health Orlando
Orlando, Florida · Recruiting
Hope And Healing Care
Hinsdale, Illinois · Recruiting
Pontchartrain Cancer Center
Covington, Louisiana · Recruiting
Mayo Clinic Rochester
Rochester, Minnesota · Recruiting
University Health Kansas City
Kansas City, Missouri · Recruiting
Intermountain Healthcare
Billings, Montana · Recruiting
Astera Cancer Center
East Brunswick, New Jersey · Recruiting
Summit Medical Group
Summit, New Jersey · Recruiting
Montefiore Medical Center
The Bronx, New York · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Hospital of the University of Pennsylvania Health System
Philadelphia, Pennsylvania · Recruiting
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania · Recruiting
Avera Cancer Institute
Sioux Falls, South Dakota · Recruiting
JPS health Network
Fort Worth, Texas · Recruiting
Utah Cancer Specialists
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.